Zydus Lifesciences’ arm receives tentative approval from USFDA for Roflumilast Tablets

17 Oct 2022 Evaluate

Zydus Lifesciences’ U.S. subsidiary--Zydus Pharmaceuticals (USA) Inc. has received tentative approval from the United States Food and Drug Administration (USFDA) to market Roflumilast Tablets USP, 250 mcg (USRLD: Daliresp).

Roflumilast Tablets are indicated as a treatment to reduce the risk of Chronic Obstructive Pulmonary Disease (COPD) exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India.

Roflumilast Tablets had annual sales of $248 million in the United States according to IQVIA data (IQVIA MAT Aug 2022). The group now has 326 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Zydus Lifesciences Share Price

884.20 -21.80 (-2.41%)
16-Mar-2026 11:56 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1775.75
Dr. Reddys Lab 1266.45
Cipla 1298.80
Zydus Lifesciences 884.20
Lupin 2277.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×